With $30M In Hand, Zosano Hopes Its Osteoporosis Patch Will Compete With Forteo
This article was originally published in The Pink Sheet Daily
Despite a long list of potential therapeutic uses for its transdermal patch technology, privately held biotech seeks direct competition in osteoporosis anabolic therapy space.
You may also be interested in...
Janssen licenses a rheumatoid arthritis program from Modern Biosciences that could address the inflammatory and bone-destruction manifestations of the disease, while Japan’s Otsuka buys Avanir on the strength of its neuroscience pipeline. Meanwhile, previously signed Astellas/Janssen and Novartis/Array agreements are terminated.
Amgen has great expectations for denosumab, but the drug still has a long road ahead and an upcoming FDA Advisory Committee review before it hits the market.
Anti-resorptive denosumab is what Amgen is counting on for its future growth. But denosumab may be the last of the current generation of drugs which prevent bone breakdown: newer drugs in development help build bone.